FindTrial
Sign In

SAMe alleviate the injury of liver function on the hepatic carcinoma patients who suffer from the hepatectomy.

SAMe alleviate the injury of liver function on the hepatic carcinoma patients who suffer from the hepatectomy: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-11001403
Enrollment
Unknown
Registered
2011-06-27
Start date
2011-02-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary hepatic carcinoma

Interventions

1:SAMe group
2:Control guoup

Sponsors

Shanghai eastern hepatobillary surgery hospital.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. 18-85 years of age; 2. Participating in the study voluntary,and sign the informed consent; 3. Geting the definite diagnose of hepatic carcinoma by B-mode ultrasonic, CT, MRI,and blood analysis; 4. Without evident dieases of heart,lung, kidney; 5. The function of liver is CHILD pugh A or nearly,without neoplasm metastasis; 6. Accord with the standard of radical operation;radical surgery.

Exclusion criteria

Exclusion criteria: 1. Rejecting to according with the standard; 2. Viloating the study,using some other medicine during the study; 3. Deficiency of major observe marker; 4. Undering some treatments such as TACE, PRFA/PMCT, chemoradiotherapy preoperative, and somebody who suffer from serious complications intraoperative or afteroperation.

Design outcomes

Primary

MeasureTime frame
Oxidative stress markers: AOPP, HNE, MDA, CAT, ORA;Total bilirubin, TP, Albumin, ALT, AST, ALP;—

Countries

China

Contacts

Public ContactLehua Shi
slhehbh@126.com+86 13601630531

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026